Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma
Open Access
- 18 June 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 24 (11) , 1495-1496
Abstract
BRAF and MEK inhibitors are highly active in the setting of BRAFV600 mutant melanoma. Rarely, patients without previous testing present with fulminant progression necessitating emergent treatment prior to BRAF testing results. The safety and efficacy of empiric treatment in this setting is unclear. Herein, we present two patients treated with empiric BRAF and MEK inhibitors, resulting in dramatic clinical improvement in one patient later found to have a BRAF mutation, and lack of improvement (but no accelerated progression) in a patient lacking this mutation. Empiric BRAF and MEK inhibitor treatment should not be routinely pursued but may be given safely in rare, emergent situations.Keywords
This publication has 7 references indexed in Scilit:
- Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2019
- Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasClinical Cancer Research, 2018
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With TrametinibJournal of Clinical Oncology, 2018
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicineLaboratory Investigation, 2018
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsEuropean Journal of Cancer, 2017
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialThe Lancet Oncology, 2017
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsNew England Journal of Medicine, 2012